NCT07520006 2026-04-13
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07502872 2026-03-31
TPG
Brown University
Phase 2 Not yet recruiting
NCT07326371 2026-01-08
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07299149 2025-12-23
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07261163 2025-12-03
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07003464 2025-06-04
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
The First Hospital of Jilin University
Phase 2 Not yet recruiting
NCT06867536 2025-03-18
GLOHRT-01
Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT06656221 2024-11-19
A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT06427213 2024-05-23
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06324994 2024-03-22
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Dalian Medical University
Phase 2 Not yet recruiting